about
Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]Generic and disease-specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional studyRetreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trialInterferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008.Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyPresence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome.Serum markers and intestinal mucosal injury in chronic gastrointestinal ischemia.Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer.Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantationEpidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands.Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response.Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice.Multistate modelling of liver transplantation data.Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease.Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome.Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding.Is there sufficient evidence to recommend antiviral therapy in hepatitis C?Drug therapies for ulcerative proctitis: systematic review and meta-analysis.Long-term survival after perforated diverticulitis.Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).Heterotopic vs. orthotopic liver transplantation for chronic liver disease: a case-control comparison of short-term and long-term outcomes.A randomized comparison of electrocautery incision with Savary bougienage for relief of anastomotic gastroesophageal strictures.Discriminant analysis using a multivariate linear mixed model with a normal mixture in the random effects distribution.On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks.The impact of infections on delisting patients from the liver transplantation waiting list.Prior radiation and/or chemotherapy has no effect on the outcome of metal stent placement for oesophagogastric carcinoma.Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B.
P50
Q24793791-80584857-2338-471F-A3B8-A3837F505AF7Q24799678-13FEFBF9-AB77-4FE4-87A2-899776E1A1CFQ24805127-6F1D0966-D4AC-4C7B-8CE9-FCC141A95BBAQ28301659-98B4E653-8015-4272-9F68-11592F2AE343Q30579693-7805876D-E333-4FCC-800E-A63DA03AD3E7Q33365990-28D76B35-E638-4BA4-A2EE-4F426B447F7AQ33375742-AA95F5B7-D229-4898-B6DA-28783741B6E8Q33390264-690E7D86-432F-4CC6-AB32-0B631F219A7EQ33414954-AB89D7A6-C950-436E-A8FD-4AC947F386D1Q33776154-4B3D5593-D12B-4E6C-827B-869C967F74A7Q34146792-0C06C2E5-28FF-4951-A3BD-0B506D906E5FQ34252292-ECF3B23B-7770-425C-B9E9-01243F7CCC5AQ34295394-2F8B6A34-9836-47B7-ADEF-F7F84B9736A4Q34534552-09413538-6834-4D50-8E41-46C992142B66Q34987596-271C9BAB-9756-497D-8DEC-E6BE6AE2D759Q35595469-37AFA3D4-5616-40B5-9CC3-8465BC86C6FCQ35596873-BD7A2DA9-6DB5-4325-A292-01CFE7EC1FE2Q35597901-84109519-2A01-4B7D-AA15-CA444A56A986Q35760507-22701DFE-0684-4127-A2DD-1194F768E1D4Q36172846-5AED3375-37F9-4D79-8B9B-805254A73020Q36457659-AD056E9E-E4D7-4A8B-8D5E-8A1FEB3ACA72Q36498837-FD5FB906-BEF3-49BC-86FD-8D7B5FAA29FEQ36698260-CE2567DE-04DA-41DD-8DF7-434E1CE2BDA2Q36865888-58DDD65D-D24C-45AC-8360-120B49E3A4A9Q36909589-F043DA84-891E-4CE8-B5E2-1F7EB66C1385Q37077799-98487B36-3C6C-42A1-8995-CC66582DDBA6Q38071650-4C03616F-9760-470E-A55A-2B9EFF4AB8F6Q38131265-0013134B-E707-4B82-8A20-42E57EF5E9B1Q38235056-AE509218-FBC6-4D25-8D17-04D702A8036FQ38448011-221E3BB6-9B5F-43C8-ADB4-8DAE273D76DFQ38454062-AD47438A-E467-4C7E-9A6A-BD3F06C18152Q39217305-349F7978-FEF3-4CA2-8B8A-8AD5A957C5FCQ39301348-92459EFD-A8BD-427A-AD6C-769C58A2F975Q39803821-B4986B4E-EFF3-40E1-8B49-D98AEA86B21EQ40006991-C79F8A56-1684-4BB7-9A07-D9FF80B04981Q40253849-8E8A7C20-BE00-43C5-BD30-76EEF7839BF8Q40536271-F97C3DB0-3B53-4E2F-98FB-21F1D53D5F34Q40822250-F6F9482E-C3F3-46FE-9820-6F5EB01D5010Q42165788-0B2C1277-3D80-4D76-98A9-0C8DCD69A0AFQ42200827-E1AE4B40-7533-469B-B76C-EAA6E9E552FD
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
B E. Hansen
@ast
B E. Hansen
@en
B E. Hansen
@es
B E. Hansen
@sl
type
label
B E. Hansen
@ast
B E. Hansen
@en
B E. Hansen
@es
B E. Hansen
@sl
altLabel
B Hansen
@en
BE Hansen
@en
Bettina E Hansen
@en
Bettina Elisabeth Hansen
@en
prefLabel
B E. Hansen
@ast
B E. Hansen
@en
B E. Hansen
@es
B E. Hansen
@sl
P1053
P-5468-2014
P106
P1153
7403015330
P31
P3829
P496
0000-0001-8307-3341